A systemic review of 7 such studies including six-hundred-eighty FLT3-mutated AML patients revealed that FLT3 inhibitor maintenance therapy significantly reduced the risk of post-transplant relapse by 65% (HR 0.35, 95% CI 0.23–0.51) and improved survival rates (HR 0.48, 95% CI 0.36–0.64) [20]. The gene discussed is FLT3; the disease is acute myeloid leukemia.